ArticleInternational journal of clinical oncology2026
Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLocal recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) or selective transarterial chemoembolization (sTACE) is relatively common. This study aimed to examine salvage hepatectomy as a treatment of such recurrences.
methodsWe retrospectively analyzed 382 patients who underwent up-front hepatectomy for treatment of HCC and 44 patients who underwent salvage hepatectomy for treatment of local recurrence after RFA or sTACE. Propensity score matching analysis was performed to account for group differences.
resultsMean time between the initial treatment and salvage hepatectomy was 3.5 ± 3.0 years. At the time of salvage hepatectomy, macroscopic vessel invasion was present in 15 patients (34.1%) and mean tumor size was significantly larger (3.0 ± 1.7 cm vs. 2.4 ± 1.1 cm; p = 0.097). Propensity score matching resulted in 33 matched pairs. After matching, 5-year overall survival did not significantly differ between the salvage and up-front hepatectomy groups. Multivariate analysis in the salvage hepatectomy group showed that serum α-fetoprotein concentration > 100 ng/mL was the only independent predictor of overall and disease-free survival.
conclusionsSalvage hepatectomy appears to be feasible for selected patients with local recurrence of HCC after RFA or sTACE.
Indexed as
Identifiers
42542508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.